AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00476255 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention (BMI)
Description: Motivational interview with trained therapist
Study NCT00790790 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: LY545694 placebo BID po for 5 weeks
Study NCT00790790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY545694 49 mg
Description: LY545694 49 mg BID po for 5 weeks.
Study NCT00790790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY545694 105 mg
Description: LY545694 105 mg BID po for 5 weeks.
Study NCT01740310 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maternal Vaccine Education
Description: It is assumed that the women will also receive vaccine education materials from the OB/GYN practices as part of routine care. The intervention for all three arms will be conducted during routine prenatal office visits. Participants will complete a baseline questionnaire to assess attitudes regarding vaccination and will then be randomized to one of three enrollment arms and will be exposed to an intervention designed to take no longer than 20 minutes, so that patients can complete it during the time they are waiting to be seen. While participants are completing the handheld/electronic tablet device-based intervention, the study recruiter will observe them and document dose exposure to the messages being presented. The enrolled women will be contacted a month after the expected date of delivery and a follow up interview will be conducted to ascertain their vaccination status for receipt of influenza vaccine in pregnancy and Tdap during pregnancy or immediately post-partum.
Study NCT01740310 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Maternal Vaccine Education
Description: It is assumed that the women will also receive vaccine education materials from the OB/GYN practices as part of routine care. The intervention for all three arms will be conducted during routine prenatal office visits. Participants will complete a baseline questionnaire to assess attitudes regarding vaccination and will then be randomized to one of three enrollment arms and will be exposed to an intervention designed to take no longer than 20 minutes, so that patients can complete it during the time they are waiting to be seen. While participants are completing the handheld/electronic tablet device-based intervention, the study recruiter will observe them and document dose exposure to the messages being presented. The enrolled women will be contacted a month after the expected date of delivery and a follow up interview will be conducted to ascertain their vaccination status for receipt of influenza vaccine in pregnancy and Tdap during pregnancy or immediately post-partum.
Study NCT04001517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neflamapimod
Description: Double-Blind, Placebo-Controlled
Study NCT04001517 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Neflamapimod
Description: Double-Blind, Placebo-Controlled
Study NCT01787773 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Veniti Inferior Vena Cava Filter
Study NCT03312309 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: personal embryo transfer
Description: According to the histological dating of endometrium of natural/hormone replacement cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer .~The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating by endometrial biopsy on 7 days after ovulation/P+7. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating were determined according to the pregnancy outcome of the FET cycle .~pET in RIF patients was delayed one(ovulation +4/P+4, OV/P+4) / two days(OV/P+3) or advanced one day(OV/P+9). Day 5 blastocysts were transferred with this strategy in natural cycles.
Study NCT01147380 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Liver NK cell inoculation
Description: Liver transplant recipients will receive once liver NK cell inoculation several days after liver transplantation.
Study NCT03783754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telmisartan 20 mg + amlodipine 2.5mg + indapamide 1.25mg
Description: low-dose combination therapy
Study NCT04191421 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Siltuximab
Description: Given IV
Study NCT04191421 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Spartalizumab
Description: Given IV
Study NCT02529293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BioChaperone Lispro U-100
Description: Injection of BioChaperone Lispro U-100
Study NCT02529293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioChaperone Lispro U-200
Description: Injection of BioChaperone Lispro U-200
Study NCT02560831 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise and Pompage
Description: Strengthening exercises for flexors and knee extensors, balance training, knee's pompage twice per week for 12 weeks.
Study NCT02560831 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational lectures
Description: Educational lectures in four meetings for 12 weeks (Control Group)
Study NCT03783754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: matched placebo
Study NCT03768869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Risk: Oupatient Management
Description: Intravenous Levaquin initially, then oral dosing. Patient discharged to go home to finish medication cycle after initial 120 minutes observation. Patients will be evaluated daily in the clinic, and his or her temperature must be taken and recorded four times per day. Blood cultures will be drawn at clinic visits.
Study NCT03241563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Deoxycholate
Study NCT03241563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: Triamcinolone 40mg/ml
Study NCT04748887 — intervention group
Intervention type: OTHER
Intervention: oxidative stess markers
Description: markers of oxidative stress , Superoxide Dismutase (SOD) and Malondialdehyde (MDA) by ( ELISA Kit SinoGeneClon Biotech Co.,Ltd Catalog No : SG- 10188) .
Study NCT04106505 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback training via app on smartphone
Description: Biofeedback training as described in biofeedback arm.
Study NCT04106505 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham-biofeedback training via app on smartphone
Description: Sham-biofeedback training as described in sham-biofeedback arm.
Study NCT04028830 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visit to GPs to promote good antibiotic prescription with the help internet tool for decision: ANTIBIOCLIC
Description: Visit to GPs to promote good antibiotic prescription with the help internet tool for decision: ANTIBIOCLIC
Study NCT04028830 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visit to GPs to promote good antibiotic prescription without presentation of the internet tool for decision support
Description: Visit to GPs to promote good antibiotic prescription without presentation of the internet tool for decision support
Study NCT00105898 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Web-based care management
Description: Participants interact with a care manager, sending and receiving messages using an internet portal that accepts uploads from glucose and BP meters
Study NCT03768869 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Risk: Inpatient Management
Description: Broad spectrum intravenous antibiotics. Daily blood work will be drawn, and patients will be monitored for fever and neutropenia in hospital.
Study NCT05097274 — intervention group
Intervention type: OTHER
Intervention: MRI pelvis or CT imaging under clinical management for Pr Ca
Description: Individuals to undergo a clinical MRI or CT scan of Pelvis and the study reviews the images.
Study NCT05097274 — intervention group
Intervention type: OTHER
Intervention: Whole body bone scan imaging
Description: bone scan of the whole body (under clinical diagnosis).
Study NCT05097274 — intervention group
Intervention type: OTHER
Intervention: PET-CT imaging
Description: Pt will undergo a PET-CT for their clinical treatment and we will review the images of this scan.
Study NCT00105898 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Telephone and face-to-face care management
Description: Participants interact with a care manager via face-to-face and telephone contact
Study NCT00105898 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Internet access alone
Description: Participants are given internet access and encouraged to seek diabetes information to help in their self management
Study NCT02733757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Clonidine 1 µg/kg plus 2% lidocaine
Study NCT02135484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpharadin
Description: 50 kBq (0.0014 mCi)/kg body weight, administered by slow intravenous injection over 1 minute every 4 weeks for 6 cycles (6 doses total).
Study NCT00895804 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MDMA
Description: capsule, 1.6 mg/kg body weight, single dose
Study NCT00895804 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pindolol
Description: capsule of 20mg pindolol, single dose 1h before MDMA
Study NCT00375258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Loading dose of 1 gram then 1 gram by infusion over 8 hours
Study NCT00375258 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9%
Description: Visual matched placebo
Study NCT02897336 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound-guided
Description: ultrasound-guided caudal epidural corticosteroid injection
Study NCT02897336 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: interlaminar
Description: interlaminar epidural corticosteroid injection
Study NCT04035226 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention will be administered as a part of this study.
Study NCT01731925 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lanreotide
Description: Lanreotide at the dose of 120 mg will be injected every 28 days as the reference treatment to control the carcinoid syndrome in both arms.
Study NCT01731925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide
Description: Lanreotide at the dose of 120 mg will be injected every 28 days as the reference treatment to control the carcinoid syndrome in both arms.
Study NCT01731925 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for sunitinib)
Study NCT01731925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib 37.5 mg daily
Study NCT04436744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Giredestrant
Description: During the window-of-opportunity phase (first 2 weeks) giredestrant will be taken orally once per day (QD) as a single agent. During the neoadjuvant treatment phase, giredestrant will be taken orally QD on Days 1-28 of each 28-day cycle for a total of 4 cycles, in combination with palbociclib.
Study NCT04436744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: During the window-of-opportunity phase (first 2 weeks), anastrozole 1 mg will be taken orally QD as a single agent. During the neoadjuvant treatment phase, anastrozole 1 mg will be taken orally QD on Days 1-28 of each 28-day cycle for a total of 4 cycles, in combination with palbociclib.
Study NCT04436744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib
Description: During the neoadjuvant treatment phase, palbociclib 125 mg will be taken orally QD on Days 1-21 of a 28-day cycle for a total of 4 cycles.
Study NCT04436744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: During the neoadjuvant treatment phase, palbociclib 125 mg will be taken orally QD on Days 1-21 of a 28-day cycle for a total of 4 cycles.
Study NCT04436744 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgery must be performed within a maximum of 14 days after the final cycle in the neoadjuvant treatment phase and ideally should occur as soon as possible after the last dose of study treatment.
Study NCT04436744 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery must be performed within a maximum of 14 days after the final cycle in the neoadjuvant treatment phase and ideally should occur as soon as possible after the last dose of study treatment.
Study NCT01133847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Appropriate dosage to be individually determined; daily for 16 weeks
Study NCT03817567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant anti-EGFR monoclonal antibody
Description: Experimental: Recombinant Anti-EGFR Monoclonal Antibody（SCT200）. Initially, SCT200 6.0mg/kg will be administered at day 1 every week for a maximum of 6 cycles. After 6 cycles SCT200 8.0mg/kg will be administered at day 2 every weeks until disease progression.
Study NCT03354819 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified MBCT
Description: Compared with the original protocol of Mindfulness-based Cognitive Therapy (Segal et al., 2002), the modified MBCT protocol in this pilot study has the following changes:~Outline:~Session 1 Awareness and automatic pilot:~Session 2 Living in our head~Session 3 Gathering the scattered mind~Session 4 Recognizing aversion \& allowing~Session 5 Thoughts are not facts~Session 6 Take care of myself~Session 7 Maintaining and extending new learning
Study NCT03354819 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SIRE on dementia
Description: The SIRE program includes routine education sessions on dementia care, caregiver skills training, and group sharing on caregiving tasks.~Outline:~1. Overview of dementia~2. Pharmacological and non-pharmacological treatment of dementia~3. BPSD in dementia care~4. Person center care~5. Advance planning in people with dementia~6. Principle of mindfulness~7. Non-pharmacological intervention on stress reduction
Study NCT05136248 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intraarticular injection
Description: Ultrasound-guided intraarticular injection
Study NCT05136248 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peng block
Description: Ultrasound-guided PENG block
Study NCT03768869 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Risk: Inpatient Management
Description: Broad spectrum intravenous antibiotics. Daily blood work will be drawn, and patients will be monitored for fever and neutropenia in hospital.
Study NCT04505982 — intervention group
Intervention type: OTHER
Intervention: Data extraction from medical files
Description: Data extraction from medical files
Study NCT03710941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN2477+REGN1033
Description: Single, sequential, repeat-dose Intravenous (IV) or matching placebo
Study NCT03710941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Single, sequential, repeat-dose Intravenous (IV)
Study NCT03016299 — intervention group
Intervention type: PROCEDURE
Intervention: microfracture techniques
Description: Drill will be performed in 3 contiguous areas. First Area by Nailing, Second by KW drilling and 3rd area drilled by regular drill obtaining a triangle with the three drilled epicenters.
Study NCT02034604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naftofidil
Study NCT02059980 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Response inhibition training
Description: This is a computerized video game that offers 40 training levels, which aims to enhance the individual's response inhibition performance
Study NCT02059980 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control Training
Description: This placebo control training looks very similar to the response inhibition training program in its appearance. However, it does not offer any practice related to response inhibition capabilities.
Study NCT04014803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dual antiplatelet therapy with a P2Y12 inhibitor plus aspirin
Description: Dual antiplatelet therapy with a P2Y12 inhibitor plus aspirin will be given according to the allocated arms in patients undergoing elective percutaneous coronary intervention for complex coronary lesion~1. Prasugrel plus Aspirin arm~2. Clopidogrel plus Aspirin arm
Study NCT03410329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Physical activity
Study NCT01821196 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: biopsies will be evaluated with immunohistochemistry and gene expression studies
Study NCT03405584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Proton pump inhibitor
Study NCT03405584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Proton pump inhibitor
Study NCT03405584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication
Study NCT03405584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication
Study NCT03405584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth Potassium Citrate
Description: Gastric mucosal protective drug with anti-H. pylori effect
Study NCT01215565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sutent
Description: Sunitinib 50mg/day (per os) for 6 cycles duration of one cycle = 6 weeks (4 weeks of treatment over 6 weeks)
Study NCT02993757 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYD Dengue Vaccine
Description: 0.5 mL, SC injection at Day 0, Month 6 and 12, respectively.
Study NCT01133847 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive reading instruction
Description: Individualized phonologically-based instruction delivered 4 days per week for 45 min. per day by a highly trained tutor.
Study NCT02993757 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYD Dengue Vaccine
Description: 0.5 mL, SC injection at Month 1, 7 and 13, respectively.
Study NCT02993757 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant.
Description: 0.5 mL, IM injection at Day 0 and Month 6, respectively.
Study NCT04067700 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Invasive coronary treatment
Description: Coronary artery bypass surgery or percutaneous coronary intervention.
Study NCT03207477 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Visual acuity measurement
Description: visual acuity measurement by Baby Vision cards at 18 months corrected age, by Rossano Weiss test at 4 years of age and optometric tests of Parinaud and Snellen at 7 years of age
Study NCT03207477 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Visual acuity measurement
Description: visual acuity measurement by Baby Vision cards at 18 months corrected age, by Rossano Weiss test at 4 years of age and optometric tests of Parinaud and Snellen at 7 years of age
Study NCT06199817 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: occupational therapies
Description: music, garden-soil and sports practices for individuals diagnosed with schizophrenic disorder
Study NCT03919331 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Assessment of tidal volume using Electrical Impedance Tomography (EIT) during high flow nasal canula(HFNC)
Description: After information and consent, patients under HFNC for de novo acute hypoxemic respiratory failure will undergo a ten minutes 4cmH2O continuous positive airway pressure(CPAP) test while monitored with 1)chest Electrical Impedance Tomography (EIT) 2) a pneumotachograph inserted on the ventilator circuit between the mask and the Y-piece and connected to a differential pressure sensor, and 3) respiratory inductance plethysmography (RIP). Airway flow signal will be acquired using an analog/digital converter and stored for further analysis with acknowledge software. This will allow converting EIT data into tidal volume (TV), and estimating TV under HFNC. RIP signals will allow evaluating asynchronism between chest and abdomen by calculating the phase angle, thus quantifying respiratory distress. Patients monitored with an arterial catheter, arterial blood gas measurements will be done during CPAP and HFNC. These measures will be collected the first day of HFNC, and everyday up to three days
Study NCT05216783 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviews
Description: The qualitative research studies performed on the traumatic childbirth experiences indicated that the pregnant women's interaction and communication with the midwives were more effective than the medical intervention methods that were applied.
Study NCT02886832 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prostate Health formulation
Study NCT00259610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: varies
Study NCT00259610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulfasalazine
Description: varies